Breast cancers have different prognoses and clinical implications based on their molecular subtypes.[13–15] Generally, the luminal type of breast cancer has been reported to have a better prognosis than either HER2 + breast cancer or TNBC. This evidence concerns the gene ERBB2 and breast carcinoma.